Cor Vasa 2026, 68(2):189-194 | DOI: 10.33678/cor.2026.042

Betablokátory v sekundární prevenci infarktu myokardu - poznatky z nových klinických studií

Petr Janský

Klinika kardiovaskulární chirurgie, 2. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Motol a Homolka, Praha, Česká republika

Beta-blockers have been used in the secondary prevention of myocardial infarction for more than forty years. A number of historical clinical studies have demonstrated a significant reduction in both mortality and morbidity when they are administered. The positive effects of beta-blockers are most pronounced in patients with left ventricular systolic dysfunction or with symptoms of heart failure. In the past two years, the results of several large randomized prospective studies have been published, clarifying the role of beta-blockers even in patients after myocardial infarction with mildly reduced or preserved left ventricular ejection fraction. While the benefit of beta-blockers is unquestionable in patients with mildly reduced systolic function, in patients with preserved systolic function the need for beta-blocker administration is rather determined by the presence of other indications, such as angina pectoris, arterial hypertension, or heart rhythm disorders, and the overall cardiovascular risk of the patient.

Keywords: Beta-blockers, Myocardial infarction, Secondary prevention,

Received: April 27, 2026; Revised: April 27, 2026; Accepted: April 30, 2026; Prepublished online: June 2, 2012; Published: May 20, 2026  Show citation